Brii Bio Achieves Preliminary NMPA Alignment for Hepatitis B Registrational Study After Mixed Phase 2b Data

Brii Bio's phase 2b hepatitis B program has delivered mixed efficacy results, yet the company has secured a meaningful regulatory foothold: preliminary alignment with China's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on a potential registrational study design for its ENRICH combination approach. For sponsors navigating China's registrational pathways, that sequencing, engaging CDE before pivotal study initiation, reflects the kind of early agency dialogue that can determine whether a program advances or stalls.

The ENRICH regimen combines investigational assets targeting hepatitis B through complementary mechanisms. Phase 2b data were mixed, meaning not all endpoints met predefined thresholds, though sufficient signal appears to have supported continued regulatory engagement. The CDE alignment suggests the agency views the approach as scientifically viable for a registrational study, a threshold that carries weight given NMPA's increasingly structured expectations around functional cure endpoints in chronic hepatitis B programs.

For regulatory affairs leads working in or entering the Chinese market, the Brii Bio trajectory illustrates a practical principle embedded in ICH Q10-aligned development thinking: iterative agency engagement during phase 2 can compress the design cycle for phase 3, particularly where endpoint definitions and patient stratification criteria require alignment before pivotal enrollment begins. China's CDE has expanded its scientific dialogue mechanisms in recent years, and sponsors who treat those channels as procedural rather than strategic tend to face longer review timelines downstream.

The mixed phase 2b outcome also carries a data integrity and study design read for clinical operations teams. Programs targeting functional cure in hepatitis B, defined broadly as sustained HBsAg loss off therapy, face inherently variable response rates across patient populations, and phase 2b designs must be powered and stratified accordingly to generate registrational-quality evidence even when top-line results are uneven.

The next measurable checkpoint is Brii Bio's formal submission of a registrational study protocol to CDE, which will test whether preliminary alignment translates into an agreed study design that satisfies NMPA's evidentiary standards for a chronic infectious disease indication.

Source: Media4Growth via Indian Pharma Post, 7 July 2026.